Thierry Burnouf earned his PhD in Science from the University of Lille, France. He currently serves as a Distinguished Professor and Vice-Dean of the College of Biomedical Engineering at Taipei Medical University (TMU), Taiwan.

Since his tenure at TMU began, Burnouf has initiated academic and research collaborations, establishing active dual MS and PhD degree programs internationally, especially with Ulille and UBFC-Besançon. He has played a crucial role in founding the NeuroTMULille international laboratory and fostering the development of a startup company between TMU and Ulille. Under his leadership, the College of Biomedical Engineering at TMU became a full partner with ILIS (Ulille), HAW (Hamburg, Germany), and IPP (Porto, Portugal) in launching the Euro-Asian Master in Medical Technology and Healthcare Business (EMMaH) through the prestigious Erasmus Mundus + program of the European Commission. He also co-leads a Horizon-Europe grant project in collaboration with Ulille, UCLouvain (Belgium), and a French company in Grenoble.

Burnouf has authored over 320 scientific publications and holds 24 patent families related to therapeutic blood-derived proteins. He serves as an advisor to the WHO on blood product quality and safety, Secretary of the "Global Blood Safety" working party, and Treasurer of the "Cellular Therapies" working party of the International Society of Blood Transfusion (ISBT). His contributions have been recognized with the 2019 Award from the International Plasma Fractionation Association for his “significant scientific advancements in plasma fractionation technologies, virus inactivation, and removal procedures”. He received the Outstanding Research Award from the Taiwan Ministry of Science and Technology in 2021 and is recently honored with the 2024 Presidential Award from ISBT.